References

Kidney cancer. Principles and practice. Second edition. Primo N. Lara, Jr. Eric Jonasch (Editors). Springer International Publishing (2015)


  1. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5(11):845–856
  2. Fuzery AK et al (2013) Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 10(1):13
  3. King SC et al (2014) Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol 191(6):1665–1670
  4. S. Cancer Statistics Working Group (2013) United States Cancer Statistics: 1999–2010 incidence and mortality web-based report. [cited 2014 Jul 25]; Available from: www.cdc.gov/uscs
  5. Linehan WM RB, Yang JC (2008) Cancer of the kidney. In: DeVita VT HS Jr, Rosenberg SA (eds) Cancer principles and practice of oncology, 8th edn. Lippincott William & Wilkins, Philadelphia, pp 1331–1354
  6. Lin L et al (2010) LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J Proteome Res 10(3):1396–1405
  7. Seliger B et al (2011) Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma? J Proteome Res 10(1):191–199
  8. Su Kim D et al (2013) Composite three-marker assay for early detection of kidney cancer. Cancer Epidemiol Biomarkers Prev 22(3):390–398
  9. Frantzi M et al (2014) Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. J Proteomics 98:44–58
  10. Nickerson ML et al (2008) Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14(15):4726–4734
  11. Zbar B et al (1987) Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327(6124):721–724
  12. Kaelin WG Jr (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8(11):865–873
  13. Gordan JD et al (2008) HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6):435–446
  14. Li M, Kim WY (2010) Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med. Epub ahead of print 15. Semenza GL (2001) HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13(2):167–171
  15. Sang N et al (2002) Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/ CBP. Mol Cell Biol 22(9):2984–2992
  16. Maynard MA et al (2003) Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278(13):11032–11040
  17. Raval RR et al (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25(13):5675–5686
  18. Rathmell WK et al (2004) HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Anticancer Res 24(1):167–169
  19. Hacker KE, Lee CM, Rathmell WK (2008) VHL type 2B mutations retain VBC complex form and function. PLoS ONE 3(11):e3801
  20. Iliopoulos O et al (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93(20):10595–10599
  21. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732
  22. Fox SB et al (2004) Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol 202(3):313–320
  23. Calvani M et al (2008) Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 68(1): 285–291
  24. Rini BI et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in
  25. patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143
  26. Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124
  27. Escudier B et al (2007) Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med 356(2): 125–134
  28. Motzer RJ et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731
  29. Ivanov S et al (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158(3):905–919
  30. Genega EM et al (2010) Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol 134(6):873–879
  31. Cancer Genome Atlas Research Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456):43–49
  32. Pantuck AJ, Fang Z, Liu X et al (2005) Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. J Clin Oncol 23(16 suppl pt 1)):Abstract 4535
  33. Hudes G et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281
  34. Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456
  35. Jonasch E et al (2010) Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57–65
  36. Atkins MB et al (2009) Treatment selection for patients with metastatic renal cell carcinoma. Cancer 115(10 Suppl):2327–2333
  37. Nishikawa M et al (2014) Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. Med Oncol 31(1):792
  38. Li S et al (2014) Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer 14(1):376
  39. Varela I et al (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331):539–542
  40. Dalgliesh GL et al (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279):360–363
  41. Pena-Llopis S et al (2012) BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 44(7):751–759
  42. Brugarolas J (2014) Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 32(18):1968–1976
  43. Pena-Llopis S et al (2013) Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res 73(14):4173–4179
  44. Toma MI et al (2008) Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10 K single nucleotide polymorphism mapping array. Neoplasia 10(7):634–642
  45. Gossage L et al (2014) Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosom Cancer 53(1):38–51
  46. Hakimi AA et al (2013) Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 19(12):3259–3267
  47. Hakimi AA et al (2013) Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 63(5):848–854
  48. Guo G et al (2012) Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 44(1):17–19
  49. Harbour JW et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410–1413
  50. Kapur P et al (2013) Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 14(2):159–167
  51. Joseph RW et al (2014) Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 120(7):1059–1067
  52. Kapur P et al (2014) BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J Urol 191(3):603–610
  53. Farley MN et al (2013) A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 11(9):1061–1071
  54. Duns G et al (2010) Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res 70(11):4287–4291
  55. Cindolo L et al (2008) Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 113(1):65–71
  56. Motzer RJ et al (2008) Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113(7):1552–1558
  57. Leibovich BC et al (2010) Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 183(4):1309–1315
  58. Frank I et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168(6):2395–2400
  59. Katz MD et al (2009) The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. Urol Oncol 29(6):738–744
  60. Molina AM et al (2010) Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol 34(5):454–459
  61. Furge KA et al (2004) Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 64(12):4117–4121
  62. Meloni-Ehrig AM (2002) Renal cancer: cytogenetic and molecular genetic aspects. Am J Med Genet 115(3):164–172
  63. Sultmann H et al (2005) Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 11(2 Pt 1):646–655
  64. Klatte T et al (2009) Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 27(5):746–753
  65. Balint I et al (2009) Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype. J Clin Pathol 62(10):892–895
  66. Kovacs G et al (1991) Cytogenetics of papillary renal cell tumors. Genes Chromosom Cancer 3(4):249–255
  67. Speicher MR et al (1994) Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 145(2):356–364
  68. Davis CF, Cherniack AD, Wang M, Yang L, Shen et al (2014) The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26(3):319–330
  69. Pawlowski R et al (2013) Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 132(2):E11–E17
  70. Takahashi M et al (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98(17):9754–9759
  71. Brannon AR et al (2010) Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 1(2):152–163
  72. Brooks SA et al (2014) ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 66(1):77–84
  73. Rini BI ZM, Aydin H et al (2010) Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). J Clin Oncol (Meet Abstr) 28(15 Suppl):4501
  74. Cifola I et al (2008) Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer 7:6
  75. Costa VL et al (2007) Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 7:133
  76. Beroukhim R et al (2009) Patterns of gene expression and copy-number alterations in von-hippel landau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69(11):4674–4681
  77. Vieira J et al (2010) Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosom Cancer 49(10):935–947
  78. Kleinrath T et al (2007) Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 25(7):845–851
  79. Kawai Y et al (2007) Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 52(4):1147–1155
  80. Xu CF et al (2011) Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 29(18):2557–2564
  81. Xu C-F et al (2015) IL8 polymorphisms and overall survival in pazopanibor sunitinib-treated patients with renal cell carcinoma. Br J Cancer. 112(7):1190–1198
  82. Scartozzi M et al (2013) VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer 108(5):1126–1132
  83. Klatte T et al (2007) Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 13(24):7388–7393
  84. Saez MI et al (2012) Hypoxia-inducible factor (HIF) 1{alpha} and 2{alpha} as predictive markers of outcome to VEGFR tyrosine kinase inhibitors (TKI) in renal cell carcinoma (RCC). J Clin Oncol 30(15_ Suppl):4630, ASCO Meeting Abstracts
  85. Garcia-Donas J et al (2013) Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol 24(9): 2409–2414
  86. Vroling L et al (2009) Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 12(1):69–79
  87. Farace F et al (2011) Levels of circulating CD45(dim) CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer 104(7):1144–1150
  88. Cangiano T et al (1999) Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17(2):523–528
  89. Motzer RJ et al (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear-cell histology. J Clin Oncol 20(9): 2376–2381
  90. Upton MP et al (2005) Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28(5):488–495
  91. McDermott DF et al (2010) The high-dose aldesleukin (HD IL-2) “SELECT” trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 28(15_Suppl):4514, ASCO Meeting Abstracts
  92. Atkins M et al (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11(10):3714–3721
  93. Jaeger E, Waldman F, Roydasgupta R et al. (2008) Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between interleukin-2 complete and non-responders. J Clin Oncol 26(15 suppl):Abstract 5043
  94. Ito N et al (2007) STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 25(19):2785–2791
  95. Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454
  96. Rini BI (2010) Biomarkers: hypertension following anti-angiogenesis therapy. Clin Adv Hematol Oncol 8(6):415–416
  97. Rini BI et al (2010) Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 28(17):e284–e285; author reply e286–7
  98. Rini BI, Cohen D, Lu D et al. (2010) Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Presented at the 2010 Genitourinary Cancers Symp [abstr 312]
  99. Choueiri TK et al (2008) von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180(3):860–865; discussion 865–866
  100. Gad S, Sultan-Amar V, Meric J et al (2007) Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results. Target Oncol 2:3–6
  101. Hutson T, Davis I, Macheils JH et al. (2008) Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. J Clin Oncol 26:Abstract 5046
  102. Pena C et al (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 16(19):4853–4863
  103. Patel PH, Chadalavada R, Ishill NM et al. (2008) Hypoxia-inducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 26:Abstract 5008
  104. Shen C et al (2011) Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov 1(3):222–235
  105. Escudier B et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20): 3312–3318
  106. Bukowski RM, Eisen T, Szczylik C et al (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25:Abstract 5023
  107. Tran HT et al (2012) Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13(8):827–837
  108. Porta C et al (2010) Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 77(9):809–815
  109. Rini BI et al (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26(22):3743–3748
  110. DePrimo SE, Bello C (2007) Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol 18(Suppl 10):x11–x19
  111. Deprimo SE et al (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32
  112. D’ Alterio C et al (2012) High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. Curr Cancer Drug Targets 12(6):693–702
  113. Zurita AJ et al (2012) A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46–52
  114. Dutcher JP et al (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26(2):202–209
  115. Plantade A, C.B., Escudier B et al. (2007) Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. J Clin Oncol 25(18 suppl):Abstract 5037
  116. Motzer RJ et al. (2014) Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 32(25):2765–2772
  117. Velickovic M et al (2002) Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 15(5):479–485
  118. Figlin RA et al (2009) Analysis of PTEN and HIF-1αlpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 115(16):3651–3660
  119. Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17(6):596–603
  120. Pantuck AJ et al (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109(11):2257–2267
  121. Youssif TA et al (2010) The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117(2):290–300
  122. Cho D et al (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5(6):379–385
  123. Voss MH et al (2014) Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res 20(7):1955–1964
  124. Bluemke K et al (2009) Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev 18(8):2190–2194
  125. Slaby O et al (2010) Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 29:90
  126. Ishihara T et al. (2014) Expression of the tumor suppressive microRNA-23b/27b cluster is a good prognostic marker in clear cell renal cell carcinoma. J Urol 192(6):1822–1830
  127. Wood SL et al (2010) Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer 103(1):101–111
  128. Dolley-Hitze T et al (2010) Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 103(11): 1698–1705
  129. Jagdev SP et al (2010) Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 103(11): 1649–1656
  130. D’Alterio C et al (2010) Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets 10(7):772–781
  131. Vasudev NS et al (2009) Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer 101(7):1175–1182
  132. Wagener N et al (2010) Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10:524
  133. Mosashvilli D et al (2010) Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci 101(12):2664–2669
  134. Ronkainen H et al (2010) HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biol 32(3):481–487
  135. Hoffmann NE et al (2008) External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 112(7):1471–1479
  136. Kawata N et al (2007) Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology 69(6):1049–1053
  137. Merseburger AS et al (2008) Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol Int 80(4):372–377
  138. Abou Youssif T et al (2011) The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117(2):290–300
  139. Zubac DP et al (2010) Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. BMC Urol 10:20
  140. Bandiera A et al (2009) Prognostic factors and analysis of S100a4 protein in resected pulmonary metastases from renal cell carcinoma. World J Surg 33(7):1414–1420
  141. Zubac DP et al (2009) The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol 182(5):2144–2149
  142. Bui MH et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9(2):802–811
  143. Tsimafeyeu I, Demidov L, Ta H et al (2010) Fibroblast growth factor pathway in renal cell carcinoma. J Clin Oncol (Meet Abstr) 28(15 Suppl): 4621
  144. Perez-Gracia JL et al (2009) Identification of TNFalpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 101(11):1876–1883
  145. Busse A et al (2011) Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-beta1 mRNA expression in peripheral blood mononuclear cells. J Immunother 34(1):113–119
  146. Heymach J, Tran H, Fritsche HA et al. (2009) Lower baseline levels of plasma hepatocyte growth factor (HGF), IL-6, IL-8 are correlated with tumor shrinkage in renal cell carcinoma patients treated with pazopanib. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Abstract A11
  147. Bukowski RM et al (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25(29):4536–4541
  148. Nixon AB et al. (2013) Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): results from CALGB 90206 (Alliance). J Clin Oncol 31(15_suppl):4520 ASCO Meeting Abstracts
  149. Armstrong AJ, George D, Halabi S et al (2010) Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). J Clin Oncol (Meet Abstr) 28(15 Suppl):4631
  150. Motzer RJ et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116(18):4256–4265
  151. Xu G et al (2009) Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma. Cancer Lett 282(2):205–213
  152. Seliger B et al (2009) Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Proteomics 9(6):1567–1581
  153. Catchpole G et al. (2009) Metabolic profiling reveals key metabolic features of renal cell carcinoma. J Cell Mol Med 15(1):109–118
  154. Kim K et al (2009) Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 8(3):558–570
  155. Zira AN et al (2010) (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. J Proteome Res 9(8):4038–4044
  156. Heinzelmann J et al (2011) Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29(3):367–373
  157. Liu H et al (2010) Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol 4:51
  158. Feng G et al (2013) Quantification of plasma cellfree DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. Dis Markers 34(2):105–111
  159. Minamimoto R et al (2011) Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. Clin Nucl Med 35(12):918–923
  160. Divgi CR et al (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8(4):304–310
  161. Spero M et al (2010) Preoperative staging of renal cell carcinoma using magnetic resonance imaging: comparison with pathological staging. Clin Imaging 34(6):441–447
  162. Wang H et al (2010) Renal cell carcinoma: diffusionweighted MR imaging for subtype differentiation at 3.0T. Radiology 257(1):135–143
  163. Hillman GG et al (2010) Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors. Transl Oncol 3(5):293–306
  164. Pedrosa I, Alsop DC, Rofsky NM (2009) Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer 115(10 Suppl):2334–2345
  165. Katz-Brull R et al (2005) Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy. Am J Physiol Renal Physiol 288(4):F637–F641
  166. Lassau N et al (2010) Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Target Oncol 5(1):53–58
  167. Choueiri et al (2013) Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin Oncol. 31(2):181–186

[contact-form-7 id=»5168″ title=»Контактная форма 1″]

0

Добавить комментарий

Войти с помощью: 

Ваш e-mail не будет опубликован. Обязательные поля помечены *